Cathay Health leads Ganymed Robotics €21M Series B to complete development of its next-gen surgical robot in preparation for commercial launch

Ganymed Robotics

July 8, 2022
Europe

The oversubscribed first close of Series B funding was led by Cathay Health, joined by Credit Mutuel Innovation, Kurma Partners and BNP Paribas Développement.

Funds will accelerate the execution of the company’s product development towards a new standard of care for knee replacement interventions.

Today, Cathay Health announces that it has led the €21M series B fund raise of Ganymed Robotics, a developer of computer vision software and robotics technologies for orthopedic surgeons. The oversubscribed first close of the round also included participation from Credit Mutuel Innovation, Kurma Partners, BNP Paribas Développement and internationally renowned surgeons.

The funding will be used to:

  • Support Ganymed’s expansion in France and in the United States
  • Finalize the industrial development of its surgical robotic assistant for knee arthroplasty (TKA)
  • Accelerate regulatory and marketing developments across geographies;
  • Diversify the innovation product pipeline

 

Since inception in 2018, Ganymed Robotics has experienced a rapid growth. In collaboration with world-class clinicians, it has validated its proprietary algorithms and collected unique in vivo data via a 100-patient observational study, successfully completed functional prototype tests, initiated industrialization of its first device dedicated to TKA through strategic partnerships with manufacturers and secured a robust patent portfolio.

“The support of this high-profile group of investors, specialized in innovation and healthcare is a strong endorsement of the work accomplished and of our vision for the future of orthopedic surgery. We are eager to enter this new phase of growth,” says Sophie Cahen, co-founder and CEO of Ganymed Robotics. “With our unique robot-with-eyes platform, we are committed to providing all surgeons and care centers, large and small, with an easy-to-use and cost-effective solution that will radically improve patient outcome, surgeon experience and overall efficiency of joint replacement interventions.”

Ganymed Robotics’ patented technology platform transforms the way orthopedic surgeons perform in the operating room, thanks to its combination of advanced computer vision and mechatronics. The first application is a co-manipulated surgical robotic assistant for total knee arthroplasty (TKA). Ganymed’s device is the first compact and intuitive robot, fully integrated into the workflow, that simplifies and increases accuracy of orthopedics. TKA is expected to rise in OECD countries from 2.4 million procedures currently to 5.7 million in 2030. Today, 95% of orthopedic surgeries are performed without technological assistance, leading to sub-optimal outcomes; patient dissatisfaction rate is above 20%.

“We’ve been incredibly impressed by Ganymeds’ next-generation technology. At Cathay Health, we look forward to working alongside such a talented team and contributing to making orthopedic surgery safer, more accessible, more surgeon-centric and ultimately more efficient for all,” says Dr. Steve Oesterle, former SVP Medicine and Technology at Medtronic, now Venture Partner at Cathay Health.

About Ganymed Robotics

Ganymed Robotics is a medical device company founded in 2018, developing the next generation of robotic assistance technologies for orthopedic surgery. The company’s mission is to improve patient outcome, surgeon experience, and overall efficiency of care delivery for its target indications. Based in Paris, Ganymed Robotics currently employs 25 people who develop a proprietary technology platform combining computer vision, a branch of artificial intelligence, and mechatronics, in close collaboration with world-class clinicians and advisors. The first application is a robotic surgical assistant for knee arthroplasties, a common and fast-growing intervention associated with high dissatisfaction rates of above 20%. Ganymed Robotics intends to progressively deploy its technology to address several other orthopedics indications. Ganymed Robotics won national and international innovation awards, such as I-Lab, French Tech Emergence, Deep Tech Pioneer, EIT Health, Wilco, EIC Accelerator. For more information: www.ganymedrobotics.com

About Cathay Health

Cathay Health, affiliated to Cathay Capital, is a global fund investing at the convergence of healthcare, life sciences and technology. As a multi-stage €500M fund, it backs venture and growth-stage companies across Europe, North America and Asia whose tech-enabled solutions catalyze groundbreaking advances in medicine. Its global platform brings together startups, established companies and large corporations to fuel cross-border, cross-industry collaboration and growth with direct access to new markets, partners and patients. From the world’s leading life sciences and technology hubs, including San Francisco, New York, London, Cambridge, Paris, Basel and Shanghai, Cathay Health partners with future leaders in the data-driven medicine era that will transform human health and care in all its dimensions.

Follow us on LinkedIn, Twitter @CathayHealth